Noninvasive Imaging Biomarker and Pathologic Complete Response to Neoadjuvant Pertuzumab/Trastuzumab in HER2-Positive Breast Cancer

Press/Media

Period	14 Dec 2023

Media coverage

Title	Noninvasive Imaging Biomarker and Pathologic Complete Response to Neoadjuvant Pertuzumab/Trastuzumab in HER2-Positive Breast Cancer
Media name/outlet	The ASCO Post
Country/Territory	United States
Date	14/12/23
URL	https://ascopost.com/news/june-2021/noninvasive-imaging-biomarker-and-pathologic-complete-response-to-neoadjuvant-pertuzumabtrastuzumab-in-her2-positive-breast-cancer/
Persons	Roisin Connolly